

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

SUMMARY

Offer Price

- The Offer Price has been determined at HK\$6.24 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%).

Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$6.24 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$78.9 million (assuming the Over-allotment Option is not exercised). The Company intends to use the net proceeds from the Global Offering in the manner as set out in the section headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is partially exercised, the Company will receive additional net proceeds of approximately HK\$17.5 million for 3,021,000 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option, after deduction of the underwriting fees and commissions and estimated expenses payable by the Company in connection with the Global Offering.

Applications and Indications of Interest Received in the Hong Kong Public Offering

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 4,032 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 14,845,000 Hong Kong Offer Shares, representing approximately 6.35 times of the total number of 2,336,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the number of Offer Shares validly applied for under the Hong Kong Public Offering represents less than 15 times of the number of Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedures as described in the section headed “Structure of the Global Offering” in the Prospectus have not been effected. There are a total number of 1,036 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, among which, 962 Shareholders, representing 92.9% of the Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, were allocated with one board lot of the Offer Shares, totalling 962,000 Shares, representing 41.2% of total Offer Shares under the Hong Kong Public Offering. The final number of Offer Shares under the Hong Kong Public Offering is 2,336,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

International Offering

- The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.34 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 21,012,000 Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total of 154 places under the International Offering, among which 95 places, representing 61.7% of the total number of places under the International Offering, have been allotted five or fewer board lots of Offer Shares, totalling 150,000 Shares, representing 0.7% of the total number of Offer Shares under the International Offering.

Over-allotment Option

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Sole Global Coordinator (on behalf of the International Underwriters), at any time from the Listing Date to the 30th day after the last day for lodging applications under the Hong Kong Public Offering (i.e. Saturday, July 30, 2022), to require the Company to allot and issue up to an aggregate of 3,502,000 additional Offer Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 3,021,000 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement, by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at www.rainmed.com and on the Stock Exchange's website at www.hkexnews.hk, respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

Lock-up Undertakings

- Each of the Company, Warranting Shareholders, and Dr. Huo Yunlong and Vermilion Bird Limited, being an existing Shareholder, is subject to certain lock-up undertakings as set out in the section headed "Lock-up Undertakings" in this announcement.

Results of Allocations

- The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on Thursday, July 7, 2022 on the website of the Stock Exchange at www.hkexnews.hk and the Company's website at www.rainmed.com.
- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares, successfully applied for, will be made available at the times and dates and in the manner specified below:
 - in the announcement to be posted on the Company's website and the Stock Exchange's website at www.rainmed.com and www.hkexnews.hk, respectively, by no later than 8:00 a.m. on Thursday, July 7, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
 - from the "IPO Results" function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Thursday, July 7, 2022 to 12:00 midnight on Wednesday, July 13, 2022; and
 - from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, July 7, 2022 to Tuesday, July 12, 2022 (excluding Saturday, Sunday and public holidays in Hong Kong).
- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed "Results of Applications Made by **HK eIPO White Form**" refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.
- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by **HK eIPO White Form**" and "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

Despatch/Collection of Share Certificates/e-Auto Refund Payment Instructions/Refund Checks

- Applicants who applied for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and who have been wholly or partially successfully allocated Hong Kong Offer Shares and are eligible to collect Share certificates in person may collect Share certificates from the Hong Kong Share Registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, July 7, 2022, or such other date as notified by the Company in the newspapers as the date of despatch/collection of Share certificates/refund monies.
- Applicants being individuals who are eligible for personal collection cannot authorize any other person to make collection on their behalf. Corporate applicants which are eligible for personal collection must attend by their authorised representatives bearing letters of authorisation from their corporations stamped with the corporations' chops. Both individuals and authorised representatives (if applicable) must produce, at the time of collection, evidence of identity acceptable to Tricor Investor Services Limited.
- Share certificates for Hong Kong Offer Shares allotted to applicants who applied for less than 1,000,000 Hong Kong Offer Shares through the **HK eIPO White Form** service are expected to be despatched to those entitled to the addresses specified in the relevant application instructions by ordinary post at their own risk on or before Thursday, July 7, 2022.
- Share certificates for Hong Kong Offer Shares allocated to applicants who applied through the **HK eIPO White Form** service which are either not available for personal collection or which are available but are not collected in person by 1:00 p.m. on Thursday, July 7, 2022, are expected to be despatched by ordinary post to those entitled to the address specified in the relevant application at their own risk on or before Thursday, July 7, 2022.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC via CCASS will have their Share certificates issued in the name of HKSCC Nominees Limited and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave **electronic application instructions** on their behalf on Thursday, July 7, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants who applied through the **HK eIPO White Form** service and paid the application monies from a single bank account will have refund monies (if any) despatched to their application payment accounts in the form of e-Auto Refund payment instructions on Thursday, July 7, 2022. Applicants who applied through the **HK eIPO White Form** service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified in their application instructions in the form of refund cheque(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at their own risk on or before Thursday, July 7, 2022. No interest will be paid thereon.

- Refund monies (if any) for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their brokers or custodians on Thursday, July 7, 2022.
- Share certificates will only become valid evidence of title at 8:00 a.m. on the Listing Date which is expected to be Friday, July 8, 2022, provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination described in the section headed "Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination" in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

Public Float

- 502,338,000 Shares, representing approximately 43.0% of the total issued share capital of the Company will be held on the hands of the public immediately following the completion of the Capitalization Issue and the Global Offering, assuming the Over-allotment Option is not exercised and the options granted under the Pre-IPO Share Option Scheme are not exercised. Accordingly, the number of Shares in public hands represents no less than 25% of the total issued share capital of the Company as required under Rule 8.08(1)(a) of the Listing Rules. The Directors confirm that the three largest public Shareholders do not hold more than 50% of the Shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) of the Listing Rules. The Directors confirm that there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules. In addition, the portion of Shares in public hands will have a market capitalization of at least HK\$375 million at the time of Listing as required under Rule 18A.07 of the Listing Rules.

Commencement of Dealings

- Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Friday, July 8, 2022 (Hong Kong time), dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, July 8, 2022 (Hong Kong time). The Shares will be traded in board lots of 1,000 Shares each. The stock code of the Shares is 2297.

Clarification

- Reference is made to the Prospectus. The Board wishes to clarify the number of Shares to be held by Shanghai Yujiaorong as of the Listing Date as set out on page 242 of the Prospectus is 8,360,000 Shares. Please refer to the section headed "Clarification" in this announcement for more details.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in Shares.

OFFER PRICE

The Offer Price has been determined at HK\$6.24 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%).

NET PROCEEDS FROM THE GLOBAL OFFERING

Based on the Offer Price of HK\$6.24 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$78.9 million (assuming the Over-allotment Option is not exercised).

The Company intends to apply the net proceeds as follows:

- (i) 80.0%, or approximately HK\$63.1 million, will be allocated to the Company's Core Products, namely, caFFR System and caIMR System:
 - 47.1%, or approximately HK\$37.2 million, will be allocated to fund the ongoing research and development, further clinical studies, preparation for registration filings, manufacturing and commercialization of the Company's caFFR System, including:
 - 31.5%, or approximately HK\$24.9 million, will be allocated to fund the Company's planned clinical trials required by the competent authorities for additional indications to cover patients with acute STEMI, acute NSTEMI and HFpEF;
 - 5.3%, or approximately HK\$4.2 million, will be allocated to fund the Company's planned overseas clinical trials and product registration of the Company's caFFR System in overseas markets;
 - 6.5%, or approximately HK\$5.1 million, will be allocated to fund the expansion of the manufacturing capacity of the Company's caFFR System; and
 - 3.8%, or approximately HK\$3.0 million, will be allocated to fund the Company's sales and marketing activities for the caFFR System in China and overseas to expand the Company's sales channels, continue patient education and sponsor academic conferences to increase the penetration rate of the Company's caFFR System.
 - 32.9%, or approximately HK\$25.9 million, will be allocated to fund the ongoing research and development, further clinical studies, preparation for registration filings, manufacturing and commercialization of the Company's caIMR System, including:
 - 15.0%, or approximately HK\$11.8 million will be allocated to fund the ongoing clinical trials of caIMR System in China;
 - 5.3%, or approximately HK\$4.2 million will be allocated to fund the Company's planned overseas clinical trials and product registration of the Company's caIMR System in overseas markets;

- 6.6%, or approximately HK\$5.2 million, will be allocated to fund the expansion of the manufacturing capacity of the Company's caIMR System; and
 - 6.0%, or approximately HK\$4.7 million, will be allocated to fund the Company's sales and marketing activities for the caIMR System in China and overseas to expand the Company's sales channels, continue patient education and sponsor academic conferences to increase the penetration rate of the Company's caIMR System.
- (ii) 16.5%, or approximately HK\$13.2 million, will be allocated to fund the ongoing research and development, manufacturing and commercialization of the Company's pipeline products, including:
- 4.5%, or approximately HK\$3.6 million, will be allocated to fund the Company's research and development and product registration of the Intelligent Angiographic Injection System in China, Europe and other emerging markets:
 - 2.5%, or approximately HK\$2.0 million, will be allocated to fund the ongoing and planned research and development activities and product registration of Intelligent Angiographic Injection System in China; and
 - 2.0%, or approximately HK\$1.6 million, will be allocated to fund the planned research and development activities and product registration of the Company's Intelligent Angiographic Injection System in the U.S. and Europe.
 - 9.0%, or approximately HK\$7.2 million, will be allocated to fund the ongoing and planned preclinical research, clinical trials and product registration of Flash Robot Vascular Intervention Navigation Operation System, including:
 - 3.0%, or approximately HK\$2.4 million, will be allocated to fund preclinical research and clinical trials of Flash Robot Vascular Intervention Navigation Operation System for coronary artery diseases;
 - 3.0%, or approximately HK\$2.4 million, will be allocated to fund preclinical research and clinical trials of Flash Robot Vascular Intervention Navigation Operation System for peripheral vascular diseases; and
 - 3.0%, or approximately HK\$2.4 million, will be allocated to fund preclinical research and clinical trials of Flash Robot Vascular Intervention Navigation Operation System for neurovascular diseases.
 - 3.0%, or approximately HK\$2.4 million, will be allocated to fund the ongoing and planned preclinical research, clinical trials and product registration of Flash RDN System;
- (iii) 3.5%, or approximately HK\$2.7 million, will be allocated to the Company's general working capital and general corporate purposes.

If the Over-allotment Option is partially exercised, the Company will receive additional net proceeds of approximately HK\$17.5 million for 3,021,000 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option. The allocation of the additional net proceeds will be adjusted on a pro-rata basis in accordance with the purposes set out in the section headed “Net Proceeds from the Global Offering” in this announcement in the event that the Over-allotment Option is exercised.

For further information, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED IN THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. At the close of the application lists at 12:00 noon on Thursday, June 30, 2022, a total of 4,032 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 14,845,000 Hong Kong Offer Shares, representing approximately 6.35 times of the total number of 2,336,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 4,030 valid applications in respect of a total of 13,045,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$6.24 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) of HK\$5 million or less, representing approximately 11.17 times of the 1,168,000 Hong Kong Offer Shares initially comprised in Pool A; and
- 2 valid applications in respect of a total of 1,800,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$6.24 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) of more than HK\$5 million, representing approximately 1.54 times of the 1,168,000 Hong Kong Offer Shares initially comprised in Pool B.

No application has been rejected due to invalid application. No multiple or suspected multiple application has been identified and rejected. No application has been rejected due to dishonored payment. No application for more than 1,168,000 Hong Kong Offer Shares (being 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the number of Offer Shares validly applied for under the Hong Kong Public Offering represents less than 15 times of the number of Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedures as described in the section headed “Structure of the Global Offering” in the Prospectus have not been effected. The final number of Offer Shares under the Hong Kong Public Offering is 2,336,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total number of 1,036 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, among which, 962 Shareholders, representing 92.9% of the Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering, were allocated with one board lot of the Offer Shares, totalling 962,000 Shares, representing 41.2% of total Offer Shares under the Hong Kong Public Offering.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the section headed “Basis of Allocation under the Hong Kong Public Offering” below.

INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering have been slightly over-subscribed, representing approximately 1.34 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 21,012,000 Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There are a total number of 154 placees under the International Offering, among which 95 placees, representing 61.7% of the total number of placees under the International Offering, have been allotted five or fewer board lots of Offer Shares, totaling 150,000 Shares, representing 0.7% of the total number of Offer Shares under the International Offering.

To the best of the knowledge of the Directors, (i) none of the Offer Shares subscribed for by the placees or the public has been financed directly or indirectly by the Company, any of the Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates and (ii) none of the placees and the members of the public who or which have subscribed for the Offer Shares is accustomed to taking instructions from the Company, any of the Directors, chief executive, substantial shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in their name or otherwise held by them.

The Directors confirm that none of the placees under the International Offering will be placed more than 10% of the enlarged issued share capital of the Company immediately after completion of the Capitalization Issue and the Global Offering. Accordingly, the Directors confirm that none of the placees will become a substantial shareholder of the Company after the International Offering, and there will not be any new substantial shareholder of the Company immediately after completion of the Capitalization Issue and the Global Offering.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Sole Global Coordinator (on behalf of the International Underwriters), at any time from the Listing Date to the 30th day after the last day for lodging applications under the Hong Kong Public Offering (i.e. Saturday, July 30, 2022), to require the Company to allot and issue up to an aggregate of 3,502,000 additional Offer Shares, representing approximately 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover the over-allocations in the International Offering, if any. There has been an over-allocation of 3,021,000 Offer Shares in the International Offering and such over-allocation will be settled by using Shares to be borrowed under the Stock Borrowing Agreement, by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Company’s website at www.rainmed.com and on the Stock Exchange’s website at www.hkexnews.hk, respectively. As of the date of this announcement, the Over-allotment Option has not been exercised.

LOCK-UP UNDERTAKINGS

Each of the Company, Warranting Shareholders, and Dr. Huo Yunlong and Vermilion Bird Limited, being an existing Shareholder, has given certain undertakings in relation to the issue or disposal of Shares (the “**Lock-up Undertakings**”). The major terms of the Lock-Up Undertakings are set out as follows:

Name	Number of Lock-up Shares held in the Company subject to the Lock-up Undertakings upon Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings upon Listing ⁽¹⁾	Last day subject to the Lock-up Undertakings
<i>The Company</i> (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)	N/A	N/A	January 8, 2023 ⁽²⁾
<i>Warranting Shareholders</i> (subject to lock-up obligations pursuant to the Hong Kong Underwriting Agreement) Mr. Huo Yunfei, Opera Rose Limited	214,749,000	18.40%	January 8, 2023 ⁽³⁾
<i>Existing shareholders</i> (subject to lock-up obligations pursuant to separate lock-up undertakings) Dr. Huo Yunlong, Vermilion Bird Limited	<u>159,934,000</u>	<u>13.70%</u>	<u>January 8, 2023⁽³⁾</u>
Total	<u>374,683,000</u>	<u>32.10%</u>	

Notes:

- (1) Based on the assumption that the Over-Allotment Option is not exercised and the options granted under the Pre-IPO Share Option Scheme are not exercised.
- (2) The Company may issue Shares without any lock-up obligation after the indicated date.
- (3) Relevant Shares can be dealt with freely on the day after the date indicated (subject to any restriction disclosed herein and in the Prospectus).

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus, 4,032 valid applications made by the public through the **HK eIPO White Form** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

Pool A			Approximate percentage allotted of the total number of Shares applied for
Number of shares applied for	Number of valid applications	Basis of allocation/ballot	
1,000	3,303	661 out of 3,303 applicants to receive 1,000 shares	20.01%
2,000	151	34 out of 151 applicants to receive 1,000 shares	11.26%
3,000	83	22 out of 83 applicants to receive 1,000 shares	8.84%
4,000	45	15 out of 45 applicants to receive 1,000 shares	8.33%
5,000	76	30 out of 76 applicants to receive 1,000 shares	7.89%
6,000	24	11 out of 24 applicants to receive 1,000 shares	7.64%
7,000	77	40 out of 77 applicants to receive 1,000 shares	7.42%
8,000	17	10 out of 17 applicants to receive 1,000 shares	7.35%
9,000	33	21 out of 33 applicants to receive 1,000 shares	7.07%
10,000	94	63 out of 94 applicants to receive 1,000 shares	6.70%
15,000	27	1,000 shares	6.67%
20,000	27	1,000 shares plus 8 out of 27 applicants to receive an additional 1,000 shares	6.48%
25,000	7	1,000 shares plus 4 out of 7 applicants to receive an additional 1,000 shares	6.29%
30,000	23	1,000 shares plus 17 out of 23 applicants to receive an additional 1,000 shares	5.80%
35,000	3	2,000 shares	5.71%
40,000	1	2,000 shares	5.00%
50,000	10	2,000 shares plus 5 out of 10 applicants to receive an additional 1,000 shares	5.00%
60,000	1	3,000 shares	5.00%
70,000	1	3,000 shares	4.29%
80,000	10	3,000 shares	3.75%
90,000	1	3,000 shares	3.33%
100,000	6	3,000 shares plus 1 out of 6 applicants to receive an additional 1,000 shares	3.17%
150,000	6	4,000 shares	2.67%
200,000	2	5,000 shares	2.50%
400,000	1	8,000 shares	2.00%
800,000	1	15,000 shares	1.88%
Total	<u>4,030</u>	Total number of Pool A successful applicants: 1,034	

Pool B

Number of shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of Shares applied for
900,000	<u>2</u>	584,000 shares	64.89%
Total	<u>2</u>	Total number of Pool B successful applicants: 2	

The final number of Offer Shares under the Hong Kong Public Offering is 2,336,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **HK eIPO White Form** services or through the **CCASS EIPO** service, including the Hong Kong identity card, passport, Hong Kong business registration or certificate of incorporation numbers of successful applicants (where applicable) and the number of Hong Kong Offer Shares successfully applied for, will be made available at the times and date and in the manner specified below:

- in the announcement to be posted on the Company’s website at www.rainmed.com and the Stock Exchange’s website at www.hkexnews.hk by no later than 8:00 a.m. on Thursday, July 7, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
- from the “IPO Results” function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Thursday, July 7, 2022 to 12:00 midnight on Wednesday, July 13, 2022; and
- from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, July 7, 2022 to Tuesday, July 12, 2022 (excluding Saturday, Sunday, and public holidays in Hong Kong).

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

The level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of application of the Hong Kong Offer Shares will be published on Thursday, July 7, 2022 on the website of the Stock Exchange at www.hkexnews.hk and the Company’s website at www.rainmed.com.

SHAREHOLDING CONCENTRATION ANALYSIS

A summary of allotment results under the International Offering is set out below:

- subscription and number of Shares held by the top 1, 5, 10, 20 and 25 placees out of the final International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Placee	Subscription	Aggregate Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised ¹)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised ¹)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised ¹)
Top 1	7,870,000	7,870,000	37.45%	32.75%	33.71%	29.85%	0.67%	0.67%
Top 5	19,148,000	19,148,000	91.13%	79.67%	82.01%	72.62%	1.64%	1.64%
Top 10	21,581,000	21,581,000	102.71%	89.80%	92.43%	81.84%	1.85%	1.84%
Top 20	23,309,000	23,309,000	110.93%	96.99%	99.83%	88.40%	2.00%	1.99%
Top 25	23,473,000	23,473,000	111.71%	97.67%	100.54%	89.02%	2.01%	2.01%

Note:

- (1) Assuming the Over-allotment Option is partially exercised up to 3,021,000 Offer Shares.

- number of Shares held by the top 1, 5, 10, 20, 25 Shareholders out of the final International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Shareholders	Subscription	Aggregate Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised ¹)	Subscription as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised ¹)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised ¹)
Top 1	-	214,749,000	-	-	-	-	18.40%	18.35%
Top 5	-	707,009,000	-	-	-	-	60.57%	60.41%
Top 10	-	924,095,000	-	-	-	-	79.16%	78.96%
Top 20	-	1,090,047,000	-	-	-	-	93.38%	93.14%
Top 25	7,870,000	1,128,045,000	37.45%	32.75%	33.71%	29.85%	96.63%	96.38%

Note:

- (1) Assuming the Over-allotment Option is partially exercised up to 3,021,000 Offer Shares.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in Shares.